Dai­ichi scores in PhI­II study of AML drug, beat­ing chemo and build­ing its case for world­wide ap­provals

An AML drug picked up by Dai­ichi Sankyo in its Am­bit buy­out has out­shone chemother­a­py in a late-stage tri­al, set­ting up the Japan­ese drug­mak­er to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.